Ting Liu

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana et al. · The Lancet Respiratory Medicine · 2019 · 268 citations

Medicine, Randomised Phase 3, Immunology +9

X-ray-responsive selenium nanoparticles for enhanced cancer chemo-radiotherapy

Bo Yu, Ting Liu, Yanxin Du et al. · Colloids and Surfaces B Biointerfaces · 2015 · 102 citations

Nanoparticles, Nanomedicine, Engineering +7

Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress

Xinmei Wang, Shanshan Li, Jiayu Yu et al. · Journal of Ethnopharmacology · 2023 · 97 citations

Inflammation, Medicine, Saikosaponin B2 +9

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

M. Pérol, Nick Pavlakis, E. Levchenko et al. · Lung Cancer · 2019 · 55 citations · Full text

Patient-reported Outcomes, Medicine, Cancer Management +6

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study

Tony Mok, Solange Peters, D. Ross Camidge et al. · Journal of Thoracic Oncology · 2020 · 38 citations · Full text